CJC-1295: The Long-Acting Growth Hormone-Releasing Hormone Analog
What Is CJC-1295?
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone (GHRH) designed to stimulate the pituitary gland to produce and release growth hormone (GH). Developed by ConjuChem Biotechnologies, CJC-1295 represents a significant advancement over native GHRH due to its dramatically extended half-life and sustained biological activity.
The peptide consists of 30 amino acids with four strategic amino acid substitutions that make it resistant to degradation by dipeptidyl peptidase-IV (DPP-IV), the enzyme that rapidly breaks down natural GHRH. While native GHRH has a half-life of only a few minutes, CJC-1295 can remain active for days – making it one of the most studied long-acting GHRH analogs available for research.
CJC-1295 Key Facts
| Property | Detail |
|---|---|
| Classification | Growth hormone-releasing hormone (GHRH) analog |
| Structure | 30-amino acid modified peptide |
| Developer | ConjuChem Biotechnologies |
| Primary Action | Stimulates pituitary GH and IGF-1 release |
| Half-Life (with DAC) | 6-8 days |
| Half-Life (without DAC) | ~30 minutes |
| Administration | Subcutaneous injection |
CJC-1295 with DAC vs. Without DAC: Understanding the Difference
One of the most important distinctions in CJC-1295 research involves the two forms of the peptide: CJC-1295 with DAC and CJC-1295 without DAC (also known as Modified GRF 1-29 or Mod GRF 1-29).
What Is DAC?
DAC stands for Drug Affinity Complex – a molecular modification that allows CJC-1295 to bind covalently to serum albumin after injection. Since albumin has a long circulating half-life, this binding dramatically extends how long CJC-1295 remains active in the bloodstream.
CJC-1295 with DAC vs. Without DAC Comparison
| Feature | CJC-1295 with DAC | CJC-1295 without DAC (Mod GRF 1-29) |
|---|---|---|
| Half-Life | 6-8 days | ~30 minutes to 2 hours |
| Dosing Frequency | Once weekly | 1-3 times daily |
| GH Release Pattern | Sustained, elevated baseline | Pulsatile, mimics natural rhythm |
| IGF-1 Elevation | 9-11 days per injection | Brief elevation per dose |
| Physiological Mimicry | Less natural (continuous) | More natural (pulsatile) |
| Dose Adjustability | Harder to titrate | Easier to adjust |
Which Version Is Preferred?
The choice between DAC and no-DAC versions depends on research objectives:
CJC-1295 with DAC is preferred for:
- Studies requiring sustained GH elevation
- Protocols with less frequent dosing
- Long-term GH axis stimulation research
CJC-1295 without DAC (Mod GRF 1-29) is preferred for:
- Studies mimicking natural pulsatile GH release
- Protocols requiring precise timing control
- Research on physiological GH secretion patterns
- Combination protocols with growth hormone-releasing peptides (GHRPs)
Many researchers prefer the no-DAC version because growth hormone is naturally released in pulses, not as a sustained elevation. The shorter-acting form allows for more physiological GH release patterns.
How CJC-1295 Works: Mechanism of Action
The GHRH Receptor Pathway
CJC-1295 works by binding to and activating GHRH receptors (GHRHR) located on somatotroph cells in the anterior pituitary gland. This triggers a cascade of intracellular signaling events:
- Receptor Binding – CJC-1295 binds to GHRHR on pituitary somatotrophs
- G-Protein Activation – The receptor couples to Gs proteins
- Adenylyl Cyclase Stimulation – Increased cyclic AMP (cAMP) production
- PKA Activation – Protein kinase A phosphorylation cascades begin
- Gene Transcription – Growth hormone gene transcription increases
- GH Synthesis and Release – Somatotrophs produce and secrete growth hormone
- IGF-1 Production – Elevated GH stimulates the liver to produce IGF-1
Preserving Pulsatile GH Secretion
One key advantage of this peptide over direct GH administration is that it works through the body’s natural regulatory systems. Research has demonstrated that even with the sustained stimulation provided by the DAC version, pulsatile GH secretion is preserved.
A study examining GH pulsatility after CJC-1295 administration found that “GH secretion was increased after CJC-1295 administration with preserved pulsatility.” The compound increased both trough (baseline) and mean GH levels while maintaining the natural pulsatile release pattern – suggesting it works with, rather than against, the body’s feedback mechanisms.
Downstream Effects: The GH-IGF-1 Axis
When CJC-1295 stimulates growth hormone release, it activates the broader GH-IGF-1 axis:
- Growth Hormone (GH) acts directly on tissues and organs
- Insulin-Like Growth Factor-1 (IGF-1) is produced primarily in the liver in response to GH
- IGF-1 mediates many of GH’s anabolic and metabolic effects
This axis influences:
- Protein synthesis and muscle growth
- Fat metabolism and lipolysis
- Bone formation and mineral density
- Cellular repair and regeneration
- Metabolic rate and energy utilization
What the Research Shows
Human Clinical Trials
The landmark study on CJC-1295 was published in the Journal of Clinical Endocrinology & Metabolism (Teichman et al., 2006). This randomized, placebo-controlled, double-blind trial examined CJC-1295 with DAC in healthy adults aged 21-61 years.
Key Findings:
| Outcome | Result |
|---|---|
| GH Increase | 2- to 10-fold increase for 6+ days after single injection |
| IGF-1 Increase | 1.5- to 3-fold increase for 9-11 days |
| Half-Life | 5.8-8.1 days |
| Multiple Dose Effect | IGF-1 remained elevated up to 28 days |
| Safety | No serious adverse reactions reported |
| Tolerability | Well tolerated, especially at 30-60 μg/kg doses |
The study concluded that “subcutaneous administration of CJC-1295 resulted in sustained, dose-dependent increases in GH and IGF-I levels in healthy adults and was safe and relatively well tolerated.”
GH Pulsatility Study
A follow-up study specifically examined whether continuous GHRH stimulation from CJC-1295 would disrupt normal GH pulsatility. Researchers used frequent blood sampling over 12-hour periods before and one week after CJC-1295 injection.
Results showed:
- GH secretion increased while pulsatility was preserved
- Both trough (minimum) and mean GH levels increased
- The enhancement of trough GH levels correlated with IGF-1 increases
- Natural pulsatile release patterns remained intact
This finding is significant because it suggests CJC-1295 augments rather than overrides the body’s natural GH secretion rhythm.
Animal Studies: Growth Normalization
Research in GHRH knockout (GHRHKO) mice – animals genetically unable to produce GHRH – demonstrated the peptide’s ability to normalize growth and body composition.
Study Design:
- Three groups of 1-week-old GHRHKO mice
- Treated with 2 μg CJC-1295 at 24, 48, or 72-hour intervals for 5 weeks
Results:
- Daily CJC-1295 administration produced normal body weight and length
- Femur and tibia length normalized with 24-48 hour dosing
- Lean mass and subcutaneous fat mass normalized in all treated groups
- Pituitary RNA and GH mRNA increased (indicating somatotroph proliferation)
- Less frequent dosing (48-72 hours) was less effective for full growth normalization
These findings demonstrate that this GHRH analog can effectively stimulate the GH axis and maintain normal growth parameters when administered appropriately.
Serum Biomarker Changes
A proteomics study examined changes in serum proteins before and after administration of the peptide in healthy young adult men. The research identified several protein changes associated with GH/IGF-1 activation:
Proteins Decreased:
- Apolipoprotein A1 isoform
- Transthyretin isoform
Proteins Increased:
- Beta-hemoglobin
- C-terminal albumin fragment
- Immunoglobulin fragment
A linear relationship was found between certain protein changes and IGF-1 levels, suggesting potential new biomarkers of GH action.
CJC-1295 and Ipamorelin: The Synergistic Combination
Why Combine CJC-1295 with Ipamorelin?
One of the most researched peptide combinations pairs this GHRH analog with Ipamorelin (a growth hormone-releasing peptide/GHRP). This combination has become popular in research because the two peptides work through different but complementary mechanisms.
How the Synergy Works
| Peptide | Receptor Target | Effect |
|---|---|---|
| CJC-1295 | GHRH receptor | Increases GH pulse frequency and duration |
| Ipamorelin | Ghrelin receptor (GHS-R1a) | Increases GH pulse amplitude |
CJC-1295:
- Acts as a GHRH analog
- Signals somatotrophs to synthesize and release GH
- Provides sustained “background” stimulation
- Increases the number of cells responding to GH release signals
Ipamorelin:
- Acts on ghrelin receptors
- Triggers immediate, potent GH release
- Amplifies the strength of each GH pulse
- Suppresses somatostatin (the GH-inhibiting hormone)
- Selectively releases GH without affecting cortisol or prolactin
Research Supporting the Combination
Studies on GHRH analog + GHSR agonist combinations have shown:
- 2-4x greater GH area under the curve (AUC) compared to either compound alone
- Additive to synergistic effects depending on timing
- Restored IGF-1 to near-normal levels more effectively than single compounds
- Preserved pulsatility maintained throughout treatment
- Approximately 20-30% higher IGF-1 elevation versus either compound alone
The combination creates conditions for maximal GH release by simultaneously:
- Stimulating the GHRH pathway (accelerator)
- Suppressing somatostatin (releasing the brake)
- Amplifying pulse strength
- Extending pulse duration
CJC-1295 + Ipamorelin vs. Other Approaches
| Approach | Pathway | Advantages | Considerations |
|---|---|---|---|
| CJC-1295 + Ipamorelin | GHRHR + GHSR | Synergistic, physiological, selective | Requires injection |
| Exogenous GH (rhGH) | Direct GH | Powerful, direct | Bypasses feedback, supraphysiological |
| CJC-1295 alone | GHRHR only | Sustained effect | Less amplitude than combination |
| Ipamorelin alone | GHSR only | Clean, selective | Shorter duration than combination |
The CJC-1295 + Ipamorelin combination is often preferred because it:
- Preserves physiological feedback mechanisms
- Avoids supraphysiological IGF-1 spikes
- Maintains natural pulsatile GH release patterns
- Has a favorable side effect profile
CJC-1295 vs. Other GHRH Analogs
CJC-1295 vs. Sermorelin
| Factor | CJC-1295 | Sermorelin |
|---|---|---|
| Structure | Modified GRF (1-29) with stability enhancements | GRF (1-29), native sequence |
| Half-Life | 30 min (no DAC) to 6-8 days (with DAC) | ~10-20 minutes |
| Stability | DPP-IV resistant | Rapidly degraded |
| Dosing Frequency | Less frequent | More frequent required |
| FDA Status | Not approved | Previously approved for GH deficiency diagnosis |
CJC-1295 vs. Tesamorelin
| Factor | CJC-1295 | Tesamorelin |
|---|---|---|
| Structure | Modified GRF (1-29) | Modified GRF (1-44) |
| FDA Approval | Not approved | FDA approved (HIV lipodystrophy) |
| Primary Use | Research | Clinical (visceral fat reduction) |
| Half-Life | Extended (especially with DAC) | ~26-38 minutes |
Potential Applications in Research
Based on the available evidence, CJC-1295 has been studied for its effects on:
Body Composition
- Increased lean body mass
- Reduced fat mass (particularly visceral fat) – see also AOD-9604 for fat metabolism research
- Improved body composition ratios
- Enhanced muscle protein synthesis
Recovery and Repair
- Accelerated tissue remodeling
- Enhanced collagen synthesis (peptides like BPC-157 are also studied for recovery)
- Improved recovery from exercise
- Support for connective tissue health
Metabolic Function
- Improved insulin sensitivity
- Enhanced glucose metabolism
- Increased metabolic rate
- Better energy utilization
Sleep and Recovery
- Enhanced deep sleep quality
- Improved sleep architecture
- Increased nocturnal GH release
- Better overall recovery
Anti-Aging Research
- Restoration of youthful GH/IGF-1 levels
- Improved skin quality and collagen production
- Enhanced cellular repair mechanisms
- Support for healthy aging (researchers also study Epithalon for longevity)
Safety and Tolerability
Clinical Trial Safety Data
In the phase I/II clinical trials, CJC-1295 was generally well tolerated:
- No serious adverse reactions reported at therapeutic doses
- Best tolerated at doses of 30-60 μg/kg
- Cumulative effects observed with multiple doses
Commonly Reported Side Effects
| Side Effect | Frequency | Notes |
|---|---|---|
| Injection site reactions | Common | Redness, swelling at injection site |
| Flushing | Common | Often temporary |
| Water retention | Common | Usually mild, resolves with time |
| Headache | Occasional | Typically mild |
| Dizziness | Occasional | Often transient |
| Tingling/numbness | Occasional | Usually in extremities |
Important Safety Considerations
Relative Contraindications:
- Active malignancy (GH/IGF-1 may influence cell growth pathways)
- Uncontrolled diabetes (GH can antagonize insulin)
- Severe cardiovascular disease
- History of cancer
Clinical Trial Discontinuation: CJC-1295 reached phase II clinical trials but was discontinued after the death of one trial participant. The attending physician believed the most likely explanation was unrelated asymptomatic coronary artery disease with plaque rupture, not the study drug. Research was terminated nonetheless as a precaution.
Regulatory Status
| Region | Status |
|---|---|
| United States | Not FDA approved; available as research chemical |
| WADA | Prohibited at all times (growth hormone secretagogue) |
| Clinical Development | Phase II trials discontinued |
Frequently Asked Questions About CJC-1295
What is CJC-1295 used for?
This peptide is a growth hormone-releasing hormone (GHRH) analog studied for its ability to stimulate natural growth hormone and IGF-1 production. Research applications include body composition, recovery, metabolic function, and anti-aging studies.
What is the difference between CJC-1295 with DAC and without DAC?
The DAC version has a half-life of 6-8 days due to albumin binding, allowing weekly dosing. The non-DAC form (Mod GRF 1-29) has a ~30-minute half-life, producing more natural pulsatile GH release but requiring more frequent dosing.
How does CJC-1295 compare to direct growth hormone injection?
This peptide stimulates the body’s own GH production through the GHRH receptor, preserving natural feedback mechanisms and pulsatile release. Direct GH injection bypasses these systems and can cause supraphysiological IGF-1 levels.
Why is CJC-1295 often combined with Ipamorelin?
The two peptides work through different receptors (GHRH receptor vs. ghrelin receptor), creating synergistic GH release greater than either compound alone. The GHRH analog extends GH pulse duration while Ipamorelin amplifies pulse strength.
Is CJC-1295 FDA approved?
No. CJC-1295 is not FDA approved for any therapeutic use. It reached phase II clinical trials but development was discontinued. It is available only as a research chemical.
What is the half-life of CJC-1295?
With DAC, the half-life is approximately 6-8 days. Without DAC (Mod GRF 1-29), the half-life is approximately 30 minutes to 2 hours.
Does CJC-1295 preserve natural GH pulsatility?
Yes. Research has shown that even with sustained stimulation from this peptide, pulsatile GH secretion is preserved, making it more physiological than direct GH administration.
The Bottom Line
This compound represents a significant advancement in growth hormone-releasing hormone analog development. Its extended half-life, ability to preserve natural pulsatile GH secretion, and demonstrated efficacy in elevating GH and IGF-1 levels make it a valuable research tool for studying the GH axis. The two forms – with DAC for sustained release and without DAC for pulsatile release – offer flexibility for different research applications. When combined with Ipamorelin, the synergistic effects provide even greater GH stimulation through complementary receptor pathways. While clinical development was discontinued, the published research provides substantial evidence for this peptide’s mechanism of action and biological effects on growth hormone secretion.
Disclaimer: This article is for educational purposes only. NexGen Peptides products are intended for laboratory research use only. Not for human consumption.
References:
- Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805.
- Alba M, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294.
- Ionescu M, Bhol RD. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797.
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561.